Tang Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Tang Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-150,000	Closed	-$21.1M	–	153
2025 Q3	$21.1M	Hold	150,000	–	–	0.81%	35
2025 Q2	$18.9M	Hold	150,000	–	–	0.95%	34
2025 Q1	$16.6M	Hold	150,000	–	–	0.92%	28
2024 Q4	$20.5M	Hold	150,000	–	–	1.35%	18
2024 Q3	$17.3M	Buy	+150,000	New	+$20.6M	1.23%	23

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Tang Capital Management's NBIX Position: Q4 2025 in Review

Tang Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 150,000 shares — an estimated $21.1M sold.

Tang Capital Management first reported a position in NBIX in Q3 2024 and held it in 5 quarters. The position peaked at $21.1M in Q3 2025. 730 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

Tang Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 150,000 Neurocrine Biosciences shares in Q4 2025, an estimated $21.1M.
Tang Capital Management first reported a position in Neurocrine Biosciences in Q3 2024 and held it in 5 quarters.
Tang Capital Management's Neurocrine Biosciences position peaked at $21.1M in Q3 2025.
730 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.